A glypican-3-derived peptide vaccine against hepatocellular carcinoma

Yu Sawada; Mayuko Sakai; Toshiaki Yoshikawa; Kazuya Ofuji; Tetsuya Nakatsura

doi:10.4161/onci.21351

A glypican-3-derived peptide vaccine against hepatocellular carcinoma

Yu Sawada, Mayuko Sakai, Toshiaki Yoshikawa, Kazuya Ofuji, Tetsuya Nakatsura

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-derived peptide vaccine.

Original language	English
Pages (from-to)	1448-1450
Number of pages	3
Journal	OncoImmunology
Volume	1
Issue number	8
DOIs	https://doi.org/10.4161/onci.21351
Publication status	Published - 2012
Externally published	Yes

Keywords

Clinical trial
Cytotoxic T lymphocyte
Glypican-3
Hepatocellular carcinoma
Peptide vaccine

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/onci.21351

Cite this

@article{fefe6c61fe80437fa17a5d6a5501c075,

title = "A glypican-3-derived peptide vaccine against hepatocellular carcinoma",

abstract = "The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-derived peptide vaccine.",

keywords = "Clinical trial, Cytotoxic T lymphocyte, Glypican-3, Hepatocellular carcinoma, Peptide vaccine",

author = "Yu Sawada and Mayuko Sakai and Toshiaki Yoshikawa and Kazuya Ofuji and Tetsuya Nakatsura",

year = "2012",

doi = "10.4161/onci.21351",

language = "English",

volume = "1",

pages = "1448--1450",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "8",

}

TY - JOUR

T1 - A glypican-3-derived peptide vaccine against hepatocellular carcinoma

AU - Sawada, Yu

AU - Sakai, Mayuko

AU - Yoshikawa, Toshiaki

AU - Ofuji, Kazuya

AU - Nakatsura, Tetsuya

PY - 2012

Y1 - 2012

N2 - The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-derived peptide vaccine.

AB - The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-derived peptide vaccine.

KW - Clinical trial

KW - Cytotoxic T lymphocyte

KW - Glypican-3

KW - Hepatocellular carcinoma

KW - Peptide vaccine

UR - http://www.scopus.com/inward/record.url?scp=84873696966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873696966&partnerID=8YFLogxK

U2 - 10.4161/onci.21351

DO - 10.4161/onci.21351

M3 - Comment/debate

AN - SCOPUS:84873696966

SN - 2162-4011

VL - 1

SP - 1448

EP - 1450

JO - OncoImmunology

JF - OncoImmunology

IS - 8

ER -

A glypican-3-derived peptide vaccine against hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this